
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is well-positioned for growth as they continue to expand their commercial team and clinical trial offerings. Their focus on breast cancer and other cancers and strong demand for their MRD test are key drivers of their future revenue goals. The company's solid financial position and strategic partnerships with industry leaders also provide a strong foundation for success and potential further expansion in the oncology market.
Bears say
Personalis is facing volatility in budgets and ordering patterns from pharma companies and is relying heavily on its NeXT Personal MRD test to drive higher levels of growth. However, there is uncertainty and risk associated with obtaining Medicare coverage for this test and achieving market penetration. Additionally, the company has incurred significant losses and may struggle to achieve profitability, and its success is heavily dependent on its commercial partner Tempus.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares